The development of activatable lytic peptides for targeting triple negative breast cancer

Cytolytic peptides are an emerging class of promising cancer therapeutics shown to overcome drug resistance. They eliminate cancer cells via disruption of the phospholipid bilayer of cell membranes, a mechanism that differentiates it from traditional treatments. However, applications of lytic peptid...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Hui, Qin, Xuan, Yang, Dan, Jiang, Yanhong, Zheng, Weihao, Wang, Dongyuan, Tian, Yuan, Liu, Qisong, Xu, Naihan, Li, Zigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629628/
https://www.ncbi.nlm.nih.gov/pubmed/29263848
http://dx.doi.org/10.1038/cddiscovery.2017.37

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629628/
https://www.ncbi.nlm.nih.gov/pubmed/29263848
http://dx.doi.org/10.1038/cddiscovery.2017.37

Ejemplares similares